Koki Sato, Country Head and GM, Takeda India talks about the company’s recent drug launch in India, its plans for the Indian market, the impact of COVID-19 on Takeda as well as the pharma sector and more, in interaction with Sanjiv Das
Takeda recently launched Kynteles for ulcerative colitis. How is the launch going to bring in a change in the gastrointestinal drug market?
With an estimated disease burden of 1.1 million Ulcerative Colitis (UC) patients and 0.3 million Crohn’s Disease (CD) patients in India, the market is in need of continuous innovation within therapies that help address inflammatory bowel disease (IBD). With the launch of Vedolizumab (Kynteles), we aim to address the treatment gap for IBD patients as it is the only gut-selective biologic available in the country.
The UC and CD adult patients who have had an inadequate response or were intolerant to either conventional therapy or were tumour necrosis factor-alpha (TNF-α) antagonist will potentially benefit from this new line of treatment. Its efficacy and integrated safety profile from clinical trials have been built based on more than 415,000 collective patient-years of exposure. Kynteles has a proven safety profile that makes it conducive for long- term treatment.
What will be your other growth plans for the Indian market?
We are building a robust product pipeline across therapeutic areas to strengthen Takeda’s commitment to patients for better health and a brighter future. We are committed to bringing our innovative therapies to patients, which will help them live a considerably improved quality of life. With the acquisition of Shire, Takeda has been able to augment this vision in India. We now have our patient offerings across portfolios like g